With these food and life changes, your body makes more of it
Vitamin D and neurodegenerative diseases
Rotate injection sites to prevent lipodystrophy (localized fat loss or hardening)
BRAUN SE: PRODUCTS OFFERED TABLE 1203 BAXTER: COMPANY OVERVIEW TABLE 1204 BAXTER: PRODUCTS OFFERED TABLE 1205 BAXTER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1206 TERUMO CORPORATION: COMPANY OVERVIEW TABLE 1207 TERUMO CORPORATION: PRODUCTS OFFERED TABLE 1208 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1209 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1210 PHILLIPS-MEDSIZE CORPORATION (MOLEX): COMPANY OVERVIEW TABLE 1211 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCTS OFFERED TABLE 1212 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1213 PHILLIPS-MEDSIZE CORPORATION (MOLEX): DEALS, JANUARY 2022MARCH 2025 TABLE 1214 PHILLIPS-MEDSIZE CORPORATION (MOLEX): EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1215 NIPRO: COMPANY OVERVIEW TABLE 1216 NIPRO: PRODUCTS OFFERED TABLE 1217 NIPRO: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1218 ICU MEDICAL, INC.: COMPANY OVERVIEW TABLE 1219 ICU MEDICAL, INC.: PRODUCTS OFFERED TABLE 1220 ICU MEDICAL, INC.: DEALS, JANUARY 2022MARCH 2025 TABLE 1221 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW TABLE 1222 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED TABLE 1223 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022MARCH 2025 TABLE 1224 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1225 GERRESHEIMER AG: COMPANY OVERVIEW TABLE 1226 GERRESHEIMER AG: PRODUCTS OFFERED TABLE 1227 GERRESHEIMER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1228 GERRESHMEIMER AG: DEALS, JANUARY 2022MARCH 2025 TABLE 1229 GERRESHMEIMER AG: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1230 STEVANATO: COMPANY OVERVIEW TABLE 1231 STEVANATO: PRODUCTS OFFERED TABLE 1232 STEVANATO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1233 STEVANATO: DEALS, JANUARY 2022MARCH 2025 TABLE 1234 STEVANATO: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1235 SCHOTT PHARMA: COMPANY OVERVIEW TABLE 1236 SCHOTT PHARMA: PRODUCTS OFFERED TABLE 1237 SCHOTT PHARMA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1238 SCHOTT PHARMA: DEALS, JANUARY 2022MARCH 2025 TABLE 1239 SCOTT PHARMA: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1240 MEDMIX: COMPANY OVERVIEW TABLE 1241 MEDMIX: PRODUCTS OFFERED TABLE 1242 MEDMIX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022MARCH 2025 TABLE 1243 MEDMIX: DEALS, JANUARY 2022APRIL 2025 TABLE 1244 SOLM: COMPANY OVERVIEW TABLE 1245 SOLM: PRODUCTS OFFERED TABLE 1246 YPSOMED: COMPANY OVERVIEW TABLE 1247 YPSOMED: PRODUCTS OFFERED TABLE 1248 YPSOMED: DEALS, JANUARY 2022MARCH 2025 TABLE 1249 YPSOMED: EXPANSIONS, JANUARY 2022MARCH 2025 TABLE 1250 OWEN MUMFORD: COMPANY OVERVIEW TABLE 1251 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW TABLE 1252 POLYMEDICURE: COMPANY OVERVIEW TABLE 1253 UNION MEDICO INC.: COMPANY OVERVIEW TABLE 1254 SHL MEDICAL: COMPANY OVERVIEW TABLE 1255 ELCAM MEDICAL: COMPANY OVERVIEW TABLE 1256 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW TABLE 1257 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED TABLE 1258 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1259 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 1260 F
Sublingual doses need to be higher than injectable doses to account for lower bioavailability
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
